Genmab A/S (GMAB)
37.48
+0.41
(+1.11%)
USD |
NASDAQ |
Oct 12, 12:22
Genmab Free Cash Flow (Quarterly) : 48.05M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.05M |
| March 31, 2026 | -2.007M |
| December 31, 2025 | 288.02M |
| September 30, 2025 | 534.97M |
| June 30, 2025 | 54.29M |
| March 31, 2025 | 257.18M |
| December 31, 2024 | 368.85M |
| September 30, 2024 | 289.64M |
| June 30, 2024 | 214.11M |
| March 31, 2024 | 216.17M |
| December 31, 2023 | 220.88M |
| September 30, 2023 | 285.27M |
| June 30, 2023 | 52.13M |
| March 31, 2023 | 451.34M |
| December 31, 2022 | 30.22M |
| September 30, 2022 | 264.07M |
| June 30, 2022 | 129.30M |
| March 31, 2022 | 79.91M |
| December 31, 2021 | 24.13M |
| September 30, 2021 | 79.91M |
| June 30, 2021 | 22.97M |
| March 31, 2021 | 187.38M |
| December 31, 2020 | -105.32M |
| September 30, 2020 | 759.99M |
| June 30, 2020 | -28.15M |
| Date | Value |
|---|---|
| March 31, 2020 | 314.66M |
| December 31, 2019 | 19.05M |
| September 30, 2019 | 42.83M |
| June 30, 2019 | 25.29M |
| March 31, 2019 | 93.88M |
| December 31, 2018 | 28.76M |
| September 30, 2018 | 30.09M |
| June 30, 2018 | 18.18M |
| March 31, 2018 | 71.84M |
| December 31, 2017 | 37.45M |
| September 30, 2017 | 8.639M |
| June 30, 2017 | 74.87M |
| March 31, 2017 | 107.23M |
| December 31, 2016 | -15.40M |
| September 30, 2016 | 30.18M |
| June 30, 2016 | 31.06M |
| March 31, 2016 | -1.883M |
| December 31, 2015 | 35.27M |
| September 30, 2015 | 20.07M |
| June 30, 2015 | -17.67M |
| March 31, 2015 | -11.34M |
| December 31, 2014 | 0.9293M |
| September 30, 2014 | 4.579M |
| June 30, 2014 | 8.814M |
| March 31, 2014 | -4.073M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AbbVie, Inc. | 3.114B |
| Ascendis Pharma A/S | 323.81M |
| Zealand Pharma A/S | 61.68M |
| Bavarian Nordic A/S | 46.98M |
| Evaxion AS | -- |